Latest Health Technology News

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

HITIQ has secured a $1.5 million R&D tax incentive loan facility and drawn half the available funding, providing immediate liquidity while adding interest-bearing debt. The arrangement with a related party also puts shareholder approval of proposed security in focus.

Gratifii Limited trimmed its net loss to $7.56 million in FY26, supported by a full-year contribution from Club Connect and a $5 million strategic investment in Marketplacer. Despite a 2.5% revenue dip, the company advanced its loyalty platform through acquisitions and AI integration.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

CONNEQT Health Limited is offering eligible shareholders a share purchase plan to raise up to $0.5 million at a 24.3% discount, aiming to fund its next growth phase in vascular health technology.

Micro-X has cleared a critical design review for its Full Body CT system, unlocking a $1.6 million milestone payment from US government partner ARPA-H and moving into prototype manufacturing.

Stakk Ltd has secured a significant U.S. healthcare technology contract, pushing its annualised revenue run rate to approximately A$26 million. The deal highlights accelerating adoption of its AI-native Digital Trust platform across regulated industries.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

Alcidion Group has acquired Telstra Health's Kyra flow products for $3 million upfront, adding 33 long-term customers and boosting recurring revenue in key Australian states.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.